Zobrazeno 1 - 10
of 12
pro vyhledávání: ''
Autor:
Mario Giuliano, Emilia Montagna, Diego D'Agostino, Sabino De Placido, Giuseppe Cancello, Monica Plaitano, Giuseppe Di Lorenzo, Michele De Laurentiis, Antonio Giordano
Publikováno v:
Breast Cancer Research : BCR
INTRODUCTION: We performed a retrospective analysis of HER2-overexpressing metastatic breast cancer patients to describe clinical outcomes of those who, despite progression of the disease (PD), maintained trastuzumab for multiple chemotherapy lines.
Autor:
Tejal Patel, Jenny C. Chang, Angel Rodriguez, Gerardo Colon-Otero, Edith A. Perez, Bhuvanesh Dave
Publikováno v:
Breast Cancer Research : BCR
The estrogen receptor and human epidermal growth factor receptor (HER) signaling pathways are the dominant drivers of cell proliferation and survival in the majority of human breast cancers. Not surprisingly, targeting these pathways provides the mos
Autor:
Sarah Kirk, Tania Szado, Lukas C. Amler, Young-Hyuck Im, Jennifer Eng-Wong, Giampaolo Bianchini, Pinuccia Valagussa, Tadeusz Pienkowski, Luca Gianni, Giulia Bianchi, Lila Zabaglo, Mitch Dowsett, Astrid Kiermaier, Mei Ching Liu, Ling Ming Tseng
Publikováno v:
Breast Cancer Research : BCR
Background NeoSphere showed significantly higher pathologic complete response (pCR) with neoadjuvant pertuzumab, trastuzumab, and docetaxel compared with trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel. We assess
Autor:
Shanu Modi, Betsy Althaus, Anthony D. Elias, Ellie Guardino, Alexander Strasak, Dan Lu, Ian E. Krop, Mark D. Pegram, Patricia LoRusso
Publikováno v:
Breast Cancer Research : BCR
Background In pre-clinical studies, the anti-tumor activity of T-DM1 was enhanced when combined with taxanes or pertuzumab. This phase 1b/2a study evaluated the safety/tolerability of T-DM1 + paclitaxel ± pertuzumab in HER2-positive advanced breast
Autor:
A. Rocca, Elisabetta Munzone, Giuseppe Renne, Aron Goldhirsch, Giuseppe Curigliano, Giuseppina Bonizzi, Franco Nolè
Publikováno v:
Breast Cancer Research
Introduction The amounts of estrogen receptor (ER) and progesterone receptor (PgR) in a primary tumor are predictive of the response to endocrine therapies of breast cancer. Several patients with ER-positive primary tumors relapse after adjuvant endo
Autor:
Jennifer K. Litton, Funda Meric-Bernstam, Tse Kuan Yu, Elizabeth A. Mittendorf, Abigail S. Caudle, Karen E. Hoffman, Susan L. Tucker, Thomas A. Buchholz, Kelly K. Hunt, Ana M. Gonzalez-Angulo, Isabelle Bedrosian
Publikováno v:
Breast Cancer Research : BCR
Introduction Breast cancers of different molecular subtypes have different survival rates. The goal of this study was to identify patients at high risk for local-regional recurrence according to response to neoadjuvant chemotherapy and surrogate mark
Autor:
Naoto T. Ueno, Gabriel N. Hortobagyi, Sabino De Placido, Mario Giuliano, Ricardo H. Alvarez, Beverly Carol Handy, James M. Reuben, Michelino De Laurentiis, Michal Mego, Massimo Cristofanilli, S. Jackson, Antonio Giordano, Kenneth R. Hess, Ugo De Giorgi, Vicente Valero
Publikováno v:
Breast Cancer Research : BCR
Introduction Circulating tumor cells (CTCs) represent an independent predictor of outcome in patients with metastatic breast cancer (MBC). We assessed the prognostic impact of CTCs according to different first-line systemic treatments, and explored t
Autor:
Vicente Vicente, Elisa Garcia-Garre, Maria Angeles Vicente Conesa, Teresa Garcia Garcia, Francisco Ayala de la Peña, Elena García-Martínez, Ginés Luengo Gil, Enrique Gonzalez-Billalabeitia, Asunción Chaves Benito
Publikováno v:
Breast Cancer Research : BCR
Introduction Tumor microenvironment immunity is associated with breast cancer outcome. A high lymphocytic infiltration has been associated with response to neoadjuvant chemotherapy, but the contribution to response and prognosis of immune cell subpop
Publikováno v:
Breast cancer research : BCR
Introduction Accurate determination of human epidermal growth factor receptor 2 (HER2) status is essential for optimal patient management with trastuzumab (Herceptin). However, standard guidelines do not specify a particular commercial kit, antibody
Autor:
Jenny C. Chang, Angel Rodriguez, Tejal Patel, Gerardo Colon-Otero, Edith A. Perez, Bhuvanesh Dave
Publikováno v:
Breast Cancer Research : BCR
The estrogen receptor and human epidermal growth factor receptor (HER) signaling pathways are the dominant drivers of cell proliferation and survival in the majority of human breast cancers. Not surprisingly, targeting these pathways provides the mos